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Abstract. Background: The purpose of this study was
to determine whether there are any patient character-
istics that predict successful use of the cephalic vein for
endocardial lead implantation.
Methods: One-hundred fifty consecutive patients
who underwent implantation of one or more endocar-
dial pacemaker (N=63) or defibrillator (N=87) leads
using a cephalic vein approach were included in this
prospective study. The mean age of the patients was
63 ± 14 years, and 115 (77%) were men. Ninty-one pa-
tients (61%) had coronary artery disease, 77 patients
(51%) had hypertension, and 42 patients (28%) had di-
abetes. The mean ejection fraction was 0.34 ± 0.17.
Results: At least one lead was successfully implanted
using a cephalic vein approach in 96 patients (64%).
The most common reason for failure of the cephalic
vein approach was a small cephalic vein, found in 25
patients (17%). Independent predictors of successful
cephalic vein use were diabetes (p< 0.001), ejection
fraction ≤0.40 (p< 0.05), and male gender (p< 0.05). At
least one endocardial lead was implanted in 19 of the 24
(79%) men who had an ejection fraction ≤0.40 and dia-
betes, compared to 4 of the 11 (36%) women who had an
ejection fraction >0.40 and did not have diabetes. The
only independent predictor of successful cephalic vein
implantation among nondiabetics was an ejection frac-
tion ≤0.40 (p< 0.01). Body size was not an independent
predictor of successful cephalic vein use.
Conclusion: Baseline patient characteristics influ-
ence the likelihood of successful endocardial lead im-
plantation using a cephalic vein approach. Diabetes,
ventricular dysfunction, male gender and are associ-
ated with an increased likelihood of a successful im-
plant using the cephalic vein. Smaller leads and and bet-
ter techniques are needed to improve the success rate
of cephalic vein implantion in all patients.
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The cephalic vein is considered by many to be the
preferred route for implantation of permanent, en-
docardial pacemaker and defibrillator leads [1–4].
However, the cephalic vein is not suitable for lead
implantation in about 15%–35% of cases [5,6]. It
is not known whether or not patient factors have
an influence on the likelihood of successful lead
implantation using the cephalic vein approach.
Therefore, the pupose of this study was to deter-
mine if there are any patient characteristics that




One-hundred fifty consecutive patients who un-
derwent implantation of one or more endocardial
pacemaker or defibrillator leads using the cephalic
vein for access, at the University of Michigan Med-
ical Center or Oakwood Medical Center, between
July 1999 and March 2001 were prospectively in-
cluded in this study.
In each patient an attempt was made to implant
at least the ventricular endocardial lead using a
standard cephalic vein approach [1]. If the pateint
also required implantation of an atrial endocar-
dial lead, an attempt was made to implant both
leads using the cephalic vein. When the implant-
ing phyiscian felt that it would be difficult to im-
plant both leads using the cephalic vein, because
the cephalic vein appeared inadequate, the subcla-
vian or axillary vein was used for the second lead.
Two patients underwent only atrial lead implan-
tation. Leads that could not be implanted via the
cephalic vein were implanted through the subcla-
vian or axillary vein using standard techniques.
Regardless of the vascular access site, each lead
was implanted through a peel-away introducer
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sheath placed over a separate guidewire. The tech-
nique of retaining the guide wire was not used.
When two leads were implanted via the cephalic
route, two guidewires were placed through the
venotomy site. The size of the sheath that was used
was the minimum French-size that could accom-
modate the lead without retaining a guidewire.
Patient Characteristics
and Implantation Details
The mean age of the patients included in this study
was 63±14 years and 115 (77%) were men. Ninty-
one patients (61%) had coronary artery disease,
77 patients (51%) had hypertension, and 42 pa-
tients (28%) had diabetes. The mean ejection frac-
tion was 0.34 ± 0.17.
Eighty-seven (58%) patients underwent defib-
rillator implantation and the remainder under-
went pacemaker implantation. Two endocardial
leads were implanted in 84 patients (56%). Most
patients (90%) underwent pacemaker and endo-
cardial lead implantation on the left side of the
chest. One-hundred fifty ventricular leads were
implanted and 84 atrial leads were implanted. The
sheath size used to implant the ventricular leads
was 8 French in 3 patients (2%), 9 French in 52
patients (38%), 10 French in 4 patients (3%), 10.5
French in 6 patients (4%), and 11 French in 71
patients (52%). The sheath size used to implant
the atrial leads was 7 French in 3 patients (4%), 8
French in 3 patients (4%), 9 French in 75 patients
(89%), and 10 French in 3 patients (4%).
Data Analysis
Continuous variables are expressed as mean ±
standard deviation and were compared using a
Student’s t-test. Nominal variables were com-
pared using a Chi-square test or Fisher’s Exact
test. Univariate analysis was performed using
the following prospectively-identified patient
characteristics to determine predictors of cephalic
vein suitability: age, gender, height, weight, body
surface area, coronary artery disease, congestive
heart failure, left ventricular ejection fraction, hy-
pertension, diabetes, peripheral vascular disease,
nitrates, beta-blockers, calcium channel blockers,
angiotensin converting enzyme inhibitors, and
alpha-blockers. Ejection fraction was analyzed
as a continuous and as a categorical variable.
Multivariate analysis was performed using binary
logistic regression on variables that were associ-
ated with a p value <0.20 by univariate analysis.
A p value <0.05 was considered statistically
significant.
Results
At least one endocardial lead was successfully
implanted using a cephalic vein approach in 96
patients (64%). Two leads were successfully im-
planted using a cephalic vein approach in 7 (9%)
of the 82 patients who required a dual-chamber
device. The remaining leads were successfully im-
planted through the subclavian vein.
There were several reasons for the failure to im-
plant at least one lead via the cephalic vein: the
cephalic vein was too small in 25 patients (17%);
the vein could not be located in 11 patients (7%);
the guide-wire could not be passed into the cen-
tral veins in 5 patients (3%); the vein tore dur-
ing sheath insertion in 1 patient (1%); other rea-
sons were present in 12 patients (8%). There was
no difference in successful use of the cepalic vein
among the five different implanting electrophysi-
ologists (p = 0.5). The introducer-sheath size used
during implantation of the ventricular lead was
slightly larger among patients who had a suc-
cessful cephalic vein implantation compared to
patients who did not have a successful cephalic
vein implantation (10.3 ± 1.0 French vs. 9.8 ± 1.0
French, respectively; p< 0.01). There were no pro-
cedural complications.
The clinical characteristics and medications in
patients who had at least one endocardial lead
successfully implanted using the cephalic vein
are compared to the patients who did not have
any lead successfully implanted using the cephalic
vein in Table 1. Variables that were entered into
the multivariate regression model included gen-
der, height, weight, body surface area, conges-
tive heart failure, ejection fraction, an ejection
fraction ≤0.40, diabetes, and the use of alpha-
blockers. The three variables that were indepen-
dent predictors of successful use of the cephalic
vein were diabetes (p< 0.01), ejection fraction
≤0.40 (p< 0.05), and male gender (p< 0.05). At
least one endocardial lead was implanted in 19
(79%) of the 24 men who had an ejection fraction
≤0.40 and diabetes, compared to 4 (36%) of the 11
women who had an ejection fraction >0.40 and no
diabetes.
A majority of patients (72%) did not have dia-
betes. Among nondiabetics, the only independent
predictor of successful cephalic vein implantation
was an ejection fraction ≤0.40 (p< 0.01).
Discussion
Main Findings
The main findings of this study are that en-
docardial lead placement via the cephalic vein
is more likely to be successful among patients
with diabetes, male gender, or an ejection fraction
≤0.40. At least one endocardial lead can be im-
planted using a cephalic vein approach in approx-
imately 80% of men with diabetes and ventricular
dysfunction.
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Table 1. Comparison of patient characteristics and medications among patients who had at least one endocardial lead placed
using the cephalic vein compared to patients who had no lead successfully implanted using the cephalic vein
Patient Successful cephalic Unsuccessful cephalic
characteristic vein implant (N = 94) vein implant (N = 56) p-value
Age (years) 62 ± 13 64 ± 15 0.430
Male 81% 67% 0.076a,b
Height (inches) 69 ± 4 67 ± 5 0.142a
Weight (pounds) 190 ± 38 177 ± 41 0.040a
Body Surface Area (m2) 2.0 ± 0.2 1.9 ± 0.3 0.032a
Coronary artery disease 67% 50% 0.045a
Congestive heart failure 64% 50% 0.106a
LV ejection fraction 32 ± 16 37 ± 18 0.062a
LV ejection fraction <0.40 74% 52% 0.023a,b
Hypertension 55% 44% 0.206
Diabetes 35% 15% 0.007a,b
Peripheral vascular disease 12% 13% 0.591
Nitrates 35% 28% 0.631
Beta-blockers 57% 48% 0.549
Calcium channel-blockers 14% 11% 0.803
ACE inhibitors 62% 56% 0.471
Alpha-blockers 21% 6% 0.013a
Abbreviations: ACE = angiotensin converting enzyme; LV = left ventricle.
aVariables entered into the logistic regression model.
bVariables found to be independently significant after multivariate analysis.
Predictors of Cephalic Vein Suitability
Any condition that is associated with a large
cephalic vein might facilitate transvenous lead im-
plantation using the cephalic vein. In fact, the
most common reason for failure of the cephalic
vein approach in this study was that the cephalic
vein was too small in 17% of patients. Male gen-
der was found to be an independent predictor of
successful cephalic vein use, however body sur-
face area was not predictive. Therefore, relative
to body size, men may have larger cephalic veins.
The finding that height and weight were not inde-
pendent predictors of successful cephalic vein use
suggest that patients with small stature should
still be considered candidates for a cephalic vein
approach.
A depressed ejection fraction was found to be a
strong independent predictor of cephalic vein suit-
ability for endocardial lead placement among both
diabetics and nondiabetics. Although the presence
of congestive heart failure was not identified to
be a predictor, there was a trend for heart fail-
ure to be more common among patients with suit-
able cephalic veins compared to patients with-
out suitable cephalic veins (64% vs 50%; p= 0.1).
Patients with ventricular dysfunction commonly
have vasoconstriction due to neurohormonal acti-
vation, but also have venous hypertension which
can lead to venous enlargement. Venous enlarge-
ment would allow for easier endocardial lead
placement.
Because diabetes causes microvascular disease
and atherosclerosis, it was surprising to find
diabetes to be a positive predictor of cephalic vein
suitablity in the present study. It is possible that
diabetics have larger cephalic veins or that dia-
betes is a marker of more severe heart failure.
Previous Studies
Despite the fact that the cephalic vein has been
used for implantation of endocardial pacing leads
for over 15 years, no prior studies have exam-
ined the clinical predictors of success. A recent
study by Calkins et al. compared the cephalic vein
approach to an extrathoracic subclavian vein ap-
proach guided by contrast venography for endo-
cardial lead placement [5]. The authors reported a
success rate for the cephalic vein approach of 64%,
which is identical to the success rate in the present
study. Other investigators have described tech-
niques to improve the success rate of cephalic vein
implantation [6], including a recent study that re-
ported an 84% success rate for single-chamber de-
vices using cephalic venography [7].
Limitations
The results of this study only apply to the implant
techniques used by the investigators. Although
there was no difference in success rate between
implanting physicians in the present study, it is
possible that alternative techniques would have
yielded a higher overall success rate of cephalic
lead implantation. Experience and technique may
influence the success rate of cephalic vein use
for lead implantation. However, the results of the
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present study suggest that patient factors are also
relevant.
Clinical Implications
The cephalic vein approach is associated with a
lower incidence of pneumothorax and lead fail-
ure compared to the subclavian vein approach
[1–5]. Therefore, many implanting physicians first
attempt to place endocardial leads through the
cephalic vein and use the subclavian vein only
if the cephalic vein is not suitable. The findings
from this study demonstrate that baseline patient
characteristics influence the likelihood of success-
ful endocardial lead implantation using a cephalic
vein approach. Although larger patients do not
appear to be more likely to have a cephalic vein
that is suitable for endocardial lead placement, pa-
tients with ventricular dysfunction or diabetes ap-
pear to be more likely to have a cephalic vein that
can be used to implant an endocardial lead, com-
pared to patients without these characteristics.
In the present study, approximately one-third of
patients did not have a cephalic vein that is suit-
able for implantation of an endocardial lead. Given
the advantages of the cephalic vein approach, it
appears that smaller leads and better techniques
are needed to improve the success rate of cephalic
vein implantion in all patients.
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